This content is machine translated Obesity treatment: new study data Incretin mimetics for comorbidities such as type 2 diabetes, ASCVD, HF, OSAS Lifestyle-related measures are the basic framework in the treatment of overweight and obesity. However, in order to achieve and maintain the target weight, accompanying pharmacological or surgical measures are usually...…
View Post 6 min This content is machine translated Incretin mimetics for obesity and prediabetes Liraglutide, semaglutide and tirzepatide: considerable evidence base Weight reduction is an important therapeutic measure in diabetes prevention. Prediabetes is characterized by elevated fasting blood sugar and/or impaired glucose tolerance, but not yet manifest diabetes. In obese people,...…
View Post 4 min This content is machine translated Semaglutide and tirzepatide in HFpEF and T2D/obesity Prospect of improved cardiovascular prognosis Patients suffering from heart failure with preserved ejection fraction (HFpEF) are very often also affected by cardiometabolic comorbidities such as obesity and type 2 diabetes. Although previous randomized trials suggest...…
View Post 9 min This content is machine translated Omega-3 fatty acids for obesity and type 2 diabetes More fish oil for better lipid and HbA1c levels Omega-3 fatty acids have an anti-inflammatory and adipogenic effect in adipose tissue. They offer systemic benefits in metabolic and chronic inflammatory diseases. By modulating inflammation and improving insulin sensitivity, they...…
View Post 4 min This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 3 min This content is machine translated Adherence of GLP1-RA Half of patients discontinue treatment within a year GLP1 receptor agonists have revolutionized the treatment of obesity, but their effectiveness depends on long-term and continuous use. However, data from Danish health registries presented at EASD 2025 show that...…
View Post 3 min This content is machine translated Development of a quintuple agonist New strategy in the fight against obesity and T2D The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists...…
View Post 11 min This content is machine translated Alternative to insulin and GLP1 From the β-cell to the center: the versatile role of amylin Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity...… CME-Test
View Post 6 min This content is machine translated Obesity as a chronic disease: an interdisciplinary perspective Neurobiological mechanisms of obesity A high-fat and high-sugar diet affects both the homeostatic hunger and satiety signals in the hypothalamus and the hedonic reward system, leading to persistent hunger and a strong craving for...…
View Post 6 min This content is machine translated Obesity in the family practice Aim for realistic goals and avoid apportioning blame Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the...…
View Post 2 min This content is machine translated "Swiss Health Care Atlas" New indicator: medication for weight regulation The healthcare atlas compiled under the auspices of Obsan documents and visualizes the frequency of medical treatments and diagnoses between cantons, regions, age groups and over time. This provides a...…
